270 related articles for article (PubMed ID: 15823493)
1. Markers of inflammation and their clinical significance.
Ballantyne CM; Nambi V
Atheroscler Suppl; 2005 May; 6(2):21-9. PubMed ID: 15823493
[TBL] [Abstract][Full Text] [Related]
2. [Inflammation, atherosclerosis and cardiovascular disease risk: PAPP-A, Lp-PLA2 and cystatin C. New insights or redundant information?].
Piñón P; Kaski JC
Rev Esp Cardiol; 2006 Mar; 59(3):247-58. PubMed ID: 16712749
[TBL] [Abstract][Full Text] [Related]
3. Lipoprotein-associated phospholipase A2: pathogenic mechanisms and clinical utility for predicting cardiovascular events.
Nambi V; Ballantyne CM
Curr Atheroscler Rep; 2006 Sep; 8(5):374-81. PubMed ID: 16901407
[TBL] [Abstract][Full Text] [Related]
4. Statins and inflammatory markers.
Case CC; Ballantyne CM
Curr Atheroscler Rep; 2002 Jan; 4(1):42-7. PubMed ID: 11772421
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory markers in coronary artery disease.
Ikonomidis I; Michalakeas CA; Parissis J; Paraskevaidis I; Ntai K; Papadakis I; Anastasiou-Nana M; Lekakis J
Biofactors; 2012; 38(5):320-8. PubMed ID: 22628054
[TBL] [Abstract][Full Text] [Related]
6. Lp-PLA2: A new target for statin therapy.
Braun LT; Davidson MH
Curr Atheroscler Rep; 2010 Jan; 12(1):29-33. PubMed ID: 20425268
[TBL] [Abstract][Full Text] [Related]
7. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
[TBL] [Abstract][Full Text] [Related]
8. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy.
Koenig W
Int J Cardiol; 2013 Oct; 168(6):5126-34. PubMed ID: 23978367
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory markers in coronary heart disease.
Madjid M; Willerson JT
Br Med Bull; 2011; 100():23-38. PubMed ID: 22010105
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory markers of coronary risk.
Rader DJ
N Engl J Med; 2000 Oct; 343(16):1179-82. PubMed ID: 11036126
[No Abstract] [Full Text] [Related]
11. [Inflammation and C-reactive protein in cardiovascular disease].
Munk PS; Larsen AI
Tidsskr Nor Laegeforen; 2009 Jun; 129(12):1221-4. PubMed ID: 19521445
[TBL] [Abstract][Full Text] [Related]
12. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany.
Koenig W; Khuseyinova N; Löwel H; Trischler G; Meisinger C
Circulation; 2004 Oct; 110(14):1903-8. PubMed ID: 15451783
[TBL] [Abstract][Full Text] [Related]
13. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker.
Corson MA; Jones PH; Davidson MH
Am J Cardiol; 2008 Jun; 101(12A):41F-50F. PubMed ID: 18549871
[TBL] [Abstract][Full Text] [Related]
14. Statins and other agents for vascular inflammation.
Owens CD
J Vasc Surg; 2012 Dec; 56(6):1799-806. PubMed ID: 23017371
[TBL] [Abstract][Full Text] [Related]
15. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?
Yousuf O; Mohanty BD; Martin SS; Joshi PH; Blaha MJ; Nasir K; Blumenthal RS; Budoff MJ
J Am Coll Cardiol; 2013 Jul; 62(5):397-408. PubMed ID: 23727085
[TBL] [Abstract][Full Text] [Related]
16. Effect of statin and fibrate treatment on inflammation in type 2 diabetes. A randomized, cross-over study.
Wägner AM; Sánchez-Quesada JL; Benítez S; Bancells C; Ordóñez-Llanos J; Pérez A
Diabetes Res Clin Pract; 2011 Jul; 93(1):e25-8. PubMed ID: 21440948
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group.
Packard CJ; O'Reilly DS; Caslake MJ; McMahon AD; Ford I; Cooney J; Macphee CH; Suckling KE; Krishna M; Wilkinson FE; Rumley A; Lowe GD
N Engl J Med; 2000 Oct; 343(16):1148-55. PubMed ID: 11036120
[TBL] [Abstract][Full Text] [Related]
18. [Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].
Sertić J; Skorić B; Lovrić J; Bozina T; Reiner Z
Acta Med Croatica; 2010 Oct; 64(4):237-45. PubMed ID: 21688606
[TBL] [Abstract][Full Text] [Related]
19. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
Ballantyne CM; Hoogeveen RC; Bang H; Coresh J; Folsom AR; Chambless LE; Myerson M; Wu KK; Sharrett AR; Boerwinkle E
Arch Intern Med; 2005 Nov; 165(21):2479-84. PubMed ID: 16314544
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory biomarkers and statins.
Blanco-Colio LM; Tuñón J; Martín-Ventura JL; Egido J
Drugs Today (Barc); 2005 Mar; 41(3):171-7. PubMed ID: 15883614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
